Chronic Obstructive Pulmonary Disease | Access and Reimbursement | US | 2017
Current market-leading therapies in the U.S. COPD market will face challenges from emerging drugs, especially generic versions of Spiriva, Symbicort, and Advair. Surveyed physicians often report that familiarity is a key driver of drug selection within a class, but clinical factors are significant both for physicians and MCOs. Cost-control measures are critical for MCOs, and have a moderate impact on prescribing decisions.
Pharmacoeconomic data are anticipated to be of increasing importance, especially with the launch of additional therapies within the LABA/LAMA class and the new LABA/LAMA/ICS FDC class.
Related Market Assessment Reports
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
